Astellas Pharma is a Japan-based pharmaceutical company with a therapeutic focus on urology, immunology (including transplantation) and infectious diseases, oncology, diabetes complications and nephrology.
The company is witnessing strong earnings growth due to sales growth of prostate cancer drug Xtandi and overactive bladder treatment drugs Vesicare and Mirabegron.
Sales growth will be boosted with the recent FDA and European Commission approvals to use Xtandi to treat patients with metastatic castration-resistant prostate cancer who have not received chemotherapy. The number of target patients for Xtandi will significantly increase (probably more than double) with this approval, therefore investment prospects are above market average.